Science & Pipeline
Deep knowledge of integrated muscle physiology
Muscle biology is exciting and complex. Every day, we explore the vast potential of this incredible organ, which plays a critical role in movement, metabolic regulation, inflammation, human growth, and other important systems within the body. Our goal is to bring muscle-targeted therapeutics to the lives of those who need them most.
Guided by our approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule drug discovery to build our proprietary, muscle-focused platform.
This knowledge informs our therapeutic development across serious musculoskeletal, cardiovascular and cardiometabolic diseases. The Edgewise team has broad experience in these disease areas, with great appreciation of the patients’ unmet needs, which our science aims to address.
Extensive, ongoing research and development across multiple, serious muscle diseases
Our commitment to a new generation of muscle therapeutics is demonstrated by our extensive research, development, and clinical programs across multiple serious muscle diseases and new areas of discovery in muscle health and its impact on the body. Our trials are designed to explore a wide range of outcomes that are meaningful for diverse patient populations with musculoskeletal, cardiovascular and cardiometabolic diseases.
Our Lead Compounds
Sevasemten
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced injury in individuals living with rare skeletal muscle disorders, including Becker and Duchenne.
EDG-7500
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, intended to slow the excessive rate of early contraction and improve impaired cardiac relaxation associated with obstructive and non-obstructive HCM, and with other diseases of diastolic dysfunction.
Sevasemten is an investigational therapy that has not been approved for use in Becker muscular dystrophy or Duchenne muscular dystrophy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
EDG-7500 is an investigational therapy that has not been approved for use in HCM or any cardiac disease by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
